Study to Evaluate the Efficacy of Zanzalintinib in the Treatment of Relapsed or Metastatic Adenoid Cystic Carcinomas of the Head and Neck

Avacta Therapeutics presents platform-validating data for faridoxorubicin in salivary gland cancer at BIO International Conference

Avacta Therapeutics announced platform-validating clinical data for faridoxorubicin (AVA6000), a tumor-activated oncology drug using its pre

New drug for cancer patients with ‘limited’ treatment options enters clinical trial

EMA begins phased review of daraxonrasib for metastatic pancreatic cancer treatment

The European Medicines Agency (EMA) has initiated a phased review of daraxonrasib, a medicine for metastatic pancreatic cancer. This acceler

Daraxonrasib drug nearly doubles survival in advanced pancreatic cancer, oncologist reports

Pancreatic cancer has extremely low survival rates (97% mortality within 5 years for metastatic cases) due to lack of effective screening an

Daraxonrasib nearly doubles survival in advanced pancreatic cancer by targeting previously 'undruggable' mechanism

A new drug called daraxonrasib has shown promise in nearly doubling survival rates for patients with advanced pancreatic cancer. Pancreatic

Pexidartinib Offers Hope for a Rare Tumor—But Its Risks Matter as You Age